![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/03/2875234/0/en/Mithra-enters-into-exclusive-negotiations-with-Gedeon-Richter-and-secures-continued-funding-in-the-context-of-its-monetization-process.html
https://www.prnewswire.com/news-releases/gedeon-richter-cariprazine-has-a-real-chance-of-becoming-the-best-selling-atypical-antipsychotic-drug-302111847.html
https://www.prnewswire.com/news-releases/gedeon-richter-selects-trial-interactive-for-clinical-trial-management-302097421.html
https://www.ema.europa.eu/en/documents/overview/ryeqo-epar-medicine-overview_en.pdf
https://www.pharmatimes.com/news/nice_draft_final_guidance_for_gedeon_richter_uks_new_uterine_fibroids_treatment_1448342
https://www.contractpharma.com/contents/view_breaking-news/2022-03-11/abbvie-and-gedeon-richter-enter-co-development-and-license-agreement/
https://www.prnewswire.com/news-releases/richter-and-hikma-sign-exclusive-commercialisation-and-license-agreement-for-denosumab-in-the-us-a-proposed-biosimilar-referencing-prolia-and-xgeva-301440878.html
https://www.ema.europa.eu/en/documents/overview/ryeqo-epar-medicine-overview_en.pdf
http://www.pharmatimes.com/news/myovant,_gedeon_richters_uterine_fibroids_med_ryeqo_bags_eu_approval_1373388